{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:51:16Z","timestamp":1789775476260,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03038-z","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T14:13:06Z","timestamp":1758118386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma\u2013a proof of concept with mifamurtide"],"prefix":"10.1007","volume":"42","author":[{"given":"Rohan","family":"Quoniou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bortoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Cachin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Chautard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Peyrode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"issue":"1","key":"3038_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41420-023-01356-7","volume":"9","author":"H Zheng","year":"2023","unstructured":"Zheng H, Peng X, Yang S, Li X, Huang M, Wei S, et al. Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy. Cell Death Discov. 2023;9(1):65. https:\/\/doi.org\/10.1038\/s41420-023-01356-7.","journal-title":"Cell Death Discov"},{"issue":"1","key":"3038_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","volume":"12","author":"M Li","year":"2022","unstructured":"Li M, He L, Zhu J, Zhang P, Liang S. Targeting tumor-associated macrophages for cancer treatment. Cell Biosci. 2022;12(1):85. https:\/\/doi.org\/10.1186\/s13578-022-00823-5.","journal-title":"Cell Biosci"},{"key":"3038_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6058147","author":"J Kim","year":"2016","unstructured":"Kim J, Bae J-S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016. https:\/\/doi.org\/10.1155\/2016\/6058147.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"3038_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010144","volume":"15","author":"J Hu","year":"2022","unstructured":"Hu J, Xu X, Du Y. Targeting tumor-associated macrophages for imaging. Pharmaceutics. 2022;15(1):144. https:\/\/doi.org\/10.3390\/pharmaceutics15010144.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3038_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78. https:\/\/doi.org\/10.1186\/s12929-019-0568-z.","journal-title":"J Biomed Sci"},{"issue":"1","key":"3038_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1):58. https:\/\/doi.org\/10.1186\/s13045-017-0430-2.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3038_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.canlet.2013.01.024","volume":"332","author":"X Tang","year":"2013","unstructured":"Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332(1):3\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2013.01.024.","journal-title":"Cancer Lett"},{"issue":"9","key":"3038_CR8","first-page":"6040","volume":"11","author":"J Xu","year":"2019","unstructured":"Xu J, Yu Y, He X, Niu N, Li X, Zhang R, et al. Tumor-associated macrophages induce invasion and poor prognosis in human gastric cancer in a cyclooxygenase-2\/MMP9-dependent manner. Am J Transl Res. 2019;11(9):6040\u201354.","journal-title":"Am J Transl Res"},{"issue":"12","key":"3038_CR9","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.7150\/ijbs.15943","volume":"12","author":"L Gan","year":"2016","unstructured":"Gan L, Qiu Z, Huang J, Li Y, Huang H, Xiang T, et al. Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway. Int J Biol Sci. 2016;12(12):1533\u201343. https:\/\/doi.org\/10.7150\/ijbs.15943.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"3038_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jor.24463","volume":"38","author":"KM Amer","year":"2020","unstructured":"Amer KM, Munn M, Congiusta D, Abraham JA, Basu Mallick A. Survival and prognosis of chondrosarcoma subtypes: SEER database analysis. J Orthop Res. 2020;38(2):311\u20139. https:\/\/doi.org\/10.1002\/jor.24463.","journal-title":"J Orthop Res"},{"issue":"9","key":"3038_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.ejso.2018.05.033","volume":"44","author":"JD Stevenson","year":"2018","unstructured":"Stevenson JD, Laitinen MK, Parry MC, Sumathi V, Grimer RJ, Jeys LM. The role of surgical margins in chondrosarcoma. Eur J Surg Oncol. 2018;44(9):1412\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2018.05.033.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"3038_CR12","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3390\/cancers15071962","volume":"15","author":"A Gilbert","year":"2023","unstructured":"Gilbert A, Tudor M, Montanari J, Commenchail K, Savu DI, Lesueur P, et al. Chondrosarcoma resistance to radiation therapy: origins and potential therapeutic solutions. Cancers. 2023;15(7):1962. https:\/\/doi.org\/10.3390\/cancers15071962.","journal-title":"Cancers"},{"issue":"7","key":"3038_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072506","volume":"12","author":"A Gazendam","year":"2023","unstructured":"Gazendam A, Popovic S, Parasu N, Ghert M. Chondrosarcoma: a clinical review. J Clin Med. 2023;12(7):2506. https:\/\/doi.org\/10.3390\/jcm12072506.","journal-title":"J Clin Med"},{"issue":"2","key":"3038_CR14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1265716","volume":"6","author":"FA Simard","year":"2017","unstructured":"Simard FA, Richert I, Vandermoeten A, Decouvelaere A-V, Michot J-P, Caux C, et al. Description of the immune microenvironment of chondrosarcoma and contribution to progression. Oncoimmunology. 2017;6(2):e1265716. https:\/\/doi.org\/10.1080\/2162402X.2016.1265716.","journal-title":"Oncoimmunology"},{"key":"3038_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100271","volume":"20","author":"I Richert","year":"2020","unstructured":"Richert I, Gomez-Brouchet A, Bouvier C, Du De Bouexic Pinieux G, Karanian M, Blay J-Y, et al. The immune landscape of chondrosarcoma - potential for therapeutic targeting of CSFR1+ macrophages. J Bone Oncol. 2020;20:100271. https:\/\/doi.org\/10.1016\/j.jbo.2019.100271.","journal-title":"J Bone Oncol"},{"issue":"1","key":"3038_CR16","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1186\/bcr3108","volume":"14","author":"PJ Boimel","year":"2012","unstructured":"Boimel PJ, Smirnova T, Zhou ZN, Wyckoff J, Park H, Coniglio SJ, et al. Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Res. 2012;14(1):R23. https:\/\/doi.org\/10.1186\/bcr3108.","journal-title":"Breast Cancer Res"},{"key":"3038_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jbo.2018.01.002","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhang X, Yang L, Xue J, Hu G. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. J Bone Oncol. 2018;11:27\u201332. https:\/\/doi.org\/10.1016\/j.jbo.2018.01.002.","journal-title":"J Bone Oncol"},{"issue":"4","key":"3038_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1345415","volume":"7","author":"MZ Noman","year":"2018","unstructured":"Noman MZ, Van Moer K, Marani V, Gemmill RM, Tranchevent L-C, Azuaje F, et al. CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT. Oncoimmunology. 2018;7(4):e1345415. https:\/\/doi.org\/10.1080\/2162402X.2017.1345415.","journal-title":"Oncoimmunology"},{"issue":"1","key":"3038_CR19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71(1):47\u201358. https:\/\/doi.org\/10.1146\/annurev-med-062518-045435.","journal-title":"Annu Rev Med"},{"issue":"18","key":"3038_CR20","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057\u201369. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3723.","journal-title":"Cancer Res"},{"issue":"2","key":"3038_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ccr.2013.01.008","volume":"23","author":"G Germano","year":"2013","unstructured":"Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23(2):249\u201362. https:\/\/doi.org\/10.1016\/j.ccr.2013.01.008.","journal-title":"Cancer Cell"},{"issue":"3","key":"3038_CR22","first-page":"677","volume":"6","author":"K Biteau","year":"2016","unstructured":"Biteau K, Guiho R, Chatelais M, Taurelle J, Chesneau J, Corradini N, et al. L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. Am J Cancer Res. 2016;6(3):677\u201389.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"3038_CR23","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23033","volume":"2","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, Burg JM, Mick R, Trosko JA, Li D, Shaik MN, et al. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013;2(1):e23033. https:\/\/doi.org\/10.4161\/onci.23033.","journal-title":"Oncoimmunology"},{"issue":"7","key":"3038_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16070865","volume":"16","author":"M-Y Li","year":"2024","unstructured":"Li M-Y, Ye W, Luo K-W. Immunotherapies targeting tumor-associated macrophages (TAMs) in cancer. Pharmaceutics. 2024;16(7):865. https:\/\/doi.org\/10.3390\/pharmaceutics16070865.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3038_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/14656566.2011.543129","volume":"12","author":"K Ando","year":"2011","unstructured":"Ando K, Mori K, Corradini N, Redini F, Heymann D. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011;12(2):285\u201392. https:\/\/doi.org\/10.1517\/14656566.2011.543129.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"3038_CR26","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/cells9041062","volume":"9","author":"M Minopoli","year":"2020","unstructured":"Minopoli M, Sarno S, Di Carluccio G, Azzaro R, Costantini S, Fazioli F, et al. Inhibiting monocyte recruitment to prevent the pro-tumoral activity of tumor-associated macrophages in chondrosarcoma. Cells. 2020;9(4):1062. https:\/\/doi.org\/10.3390\/cells9041062.","journal-title":"Cells"},{"issue":"10","key":"3038_CR27","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3390\/cancers13102408","volume":"13","author":"JI Traylor","year":"2021","unstructured":"Traylor JI, Pernik MN, Plitt AR, Lim M, Garzon-Muvdi T. Immunotherapy for chordoma and chondrosarcoma: current evidence. Cancers (Basel). 2021;13(10):2408. https:\/\/doi.org\/10.3390\/cancers13102408.","journal-title":"Cancers (Basel)"},{"issue":"19","key":"3038_CR28","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1111\/1759-7714.14613","volume":"13","author":"R Ogata","year":"2022","unstructured":"Ogata R, Soda H, Senju H, Fujioka M, Shimada M, Yamashita K, et al. Immunosuppressive tumor microenvironment in extraskeletal myxoid chondrosarcoma: a case of pleural metastases. Thorac Cancer. 2022;13(19):2812\u20136. https:\/\/doi.org\/10.1111\/1759-7714.14613.","journal-title":"Thorac Cancer"},{"issue":"8","key":"3038_CR29","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14(8):561\u201384. https:\/\/doi.org\/10.1038\/nrd4591.","journal-title":"Nat Rev Drug Discov"},{"key":"3038_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","volume":"419","author":"J Wu","year":"2018","unstructured":"Wu J, Waxman DJ. Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy. Cancer Lett. 2018;419:210\u201321. https:\/\/doi.org\/10.1016\/j.canlet.2018.01.050.","journal-title":"Cancer Lett"},{"issue":"9","key":"3038_CR31","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0192-0561(00)00028-X","volume":"22","author":"S Kadhim","year":"2000","unstructured":"Kadhim S, Penney C, Lagraoui M, Heibein J, Attardo G, Zacharie B, et al. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393 Combination with Cyclophosphamide. Int J Immunopharmacol. 2000;22(9):659\u201371. https:\/\/doi.org\/10.1016\/S0192-0561(00)00028-X.","journal-title":"Int J Immunopharmacol"},{"issue":"2","key":"3038_CR32","first-page":"551","volume":"12","author":"J Hong","year":"2020","unstructured":"Hong J, Jing S, Zhang Y, Chen R, Owusu-Ansah KG, Chen B, et al. Y-320, a novel immune-modulator, sensitizes multidrug-resistant tumors to chemotherapy. Am J Transl Res. 2020;12(2):551\u201362.","journal-title":"Am J Transl Res"},{"key":"3038_CR33","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.4c00625","author":"R Quoniou","year":"2024","unstructured":"Quoniou R, Moreau E, Cachin F, Blavignac C, Bortoli E, Chautard E, et al. Chondrosarcoma co-culture 3D model\u2500an insight to evaluate drugs acting on TAMs. ACS Biomater Sci Eng. 2024. https:\/\/doi.org\/10.1021\/acsbiomaterials.4c00625.","journal-title":"ACS Biomater Sci Eng"},{"issue":"2","key":"3038_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ijc.10472","volume":"100","author":"M Raitanen","year":"2002","unstructured":"Raitanen M, Rantanen V, Kulmala J, Helenius H, Gr\u00e9nman R, Gr\u00e9nman S. Supra-additive effect with concurrent Paclitaxel and Cisplatin in vulvar squamous cell carcinoma in vitro. Int J Cancer. 2002;100(2):238\u201343. https:\/\/doi.org\/10.1002\/ijc.10472.","journal-title":"Int J Cancer"},{"issue":"7","key":"3038_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181340","volume":"12","author":"A Voissiere","year":"2017","unstructured":"Voissiere A, Jouberton E, Maubert E, Degoul F, Peyrode C, Chezal J-M, et al. Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. PLoS ONE. 2017;12(7):e0181340. https:\/\/doi.org\/10.1371\/journal.pone.0181340.","journal-title":"PLoS ONE"},{"issue":"21","key":"3038_CR36","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.3390\/cancers15215294","volume":"15","author":"AE Zaj\u0105c","year":"2023","unstructured":"Zaj\u0105c AE, Czarnecka AM, Rutkowski P. The role of macrophages in sarcoma tumor microenvironment and treatment. Cancers. 2023;15(21):5294. https:\/\/doi.org\/10.3390\/cancers15215294.","journal-title":"Cancers"},{"issue":"9","key":"3038_CR37","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.3390\/cancers15092556","volume":"15","author":"SG Walter","year":"2023","unstructured":"Walter SG, Kn\u00f6ll P, Eysel P, Quaas A, Gaisendrees C, Ni\u00dfler R, et al. Molecular in-depth characterization of chondrosarcoma for current and future targeted therapies. Cancers (Basel). 2023;15(9):2556. https:\/\/doi.org\/10.3390\/cancers15092556.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"3038_CR38","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1093\/jnci\/djn240","volume":"100","author":"PD Ottewell","year":"2008","unstructured":"Ottewell PD, M\u00f6nkk\u00f6nen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008;100(16):1167\u201378. https:\/\/doi.org\/10.1093\/jnci\/djn240.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"3038_CR39","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.21873\/anticanres.13662","volume":"39","author":"T Higuchi","year":"2019","unstructured":"Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, et al. Combination treatment with sorafenib and everolimus regresses a doxorubicin-resistant osteosarcoma in a PDOX mouse model. Anticancer Res. 2019;39(9):4781\u20136. https:\/\/doi.org\/10.21873\/anticanres.13662.","journal-title":"Anticancer Res"},{"issue":"4","key":"3038_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010365","volume":"5","author":"A Bandyopadhyay","year":"2010","unstructured":"Bandyopadhyay A, Wang L, Agyin J, Tang Y, Lin S, Yeh I-T, et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS ONE. 2010;5(4):e10365. https:\/\/doi.org\/10.1371\/journal.pone.0010365.","journal-title":"PLoS ONE"},{"issue":"1","key":"3038_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1021\/acsbiomaterials.3c01437","volume":"10","author":"R Quoniou","year":"2024","unstructured":"Quoniou R, Moreau E, Cachin F, Miot-Noirault E, Chautard E, Peyrode C. 3D coculture between cancer cells and macrophages: from conception to experimentation. ACS Biomater Sci Eng. 2024;10(1):313\u201325. https:\/\/doi.org\/10.1021\/acsbiomaterials.3c01437.","journal-title":"ACS Biomater Sci Eng"},{"issue":"22","key":"3038_CR42","doi-asserted-by":"publisher","first-page":"12200","DOI":"10.3390\/ijms222212200","volume":"22","author":"O Habanjar","year":"2021","unstructured":"Habanjar O, Diab-Assaf M, Caldefie-Chezet F, Delort L. 3D cell culture systems: tumor application, advantages, and disadvantages. Int J Mol Sci. 2021;22(22):12200. https:\/\/doi.org\/10.3390\/ijms222212200.","journal-title":"Int J Mol Sci"},{"key":"3038_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.123810","author":"X Fang","year":"2023","unstructured":"Fang X, Zhao P, Gao S, Liu D, Zhang S, Shan M, et al. Lactate induces tumor-associated macrophage polarization independent of mitochondrial pyruvate carrier-mediated metabolism. Int J Biol Macromol. 2023. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123810.","journal-title":"Int J Biol Macromol"},{"key":"3038_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2023.113157","volume":"223","author":"C Chen","year":"2023","unstructured":"Chen C, Zhang W, Lu S-Y, Wang J, Tan Y, Zhao S, et al. Repolarizing tumor-associated macrophages by layered double hydroxide-based deacidification agent for tumor chemodynamic therapy and immunotherapy. Colloids Surf, B. 2023;223:113157. https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113157.","journal-title":"Colloids Surf, B"},{"issue":"1","key":"3038_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5487\/TR.2014.30.1.001","volume":"30","author":"J Jung","year":"2014","unstructured":"Jung J. Human tumor xenograft models for preclinical assessment of anticancer drug development. Toxicol Res. 2014;30(1):1\u20135. https:\/\/doi.org\/10.5487\/TR.2014.30.1.001.","journal-title":"Toxicol Res"},{"key":"3038_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.598001","volume":"11","author":"SPFT Nota","year":"2021","unstructured":"Nota SPFT, Al-Sukaini A, Patel SS, Sabbatino F, Nielsen GP, Deshpande V, et al. High TIL, HLA, and immune checkpoint expression in conventional high-grade and dedifferentiated chondrosarcoma and poor clinical course of the disease. Front Oncol. 2021;11:598001. https:\/\/doi.org\/10.3389\/fonc.2021.598001.","journal-title":"Front Oncol"},{"issue":"9","key":"3038_CR47","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/modpathol.2016.108","volume":"29","author":"M Kostine","year":"2016","unstructured":"Kostine M, Cleven AH, de Miranda NFCC, Italiano A, Cleton-Jansen A-M, Bov\u00e9e JVMG. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol Off J U S Can Acad Pathol Inc. 2016;29(9):1028\u201337. https:\/\/doi.org\/10.1038\/modpathol.2016.108.","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc"},{"issue":"4\u20135","key":"3038_CR48","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/03008207.2013.806913","volume":"54","author":"JW Stevens","year":"2013","unstructured":"Stevens JW. Swarm chondrosarcoma: a continued resource for chondroblastic-like extracellular matrix and chondrosarcoma biology research. Connect Tissue Res. 2013;54(4\u20135):252\u20139. https:\/\/doi.org\/10.3109\/03008207.2013.806913.","journal-title":"Connect Tissue Res"},{"issue":"7","key":"3038_CR49","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/annonc\/mdw041","volume":"27","author":"MF Sanmamed","year":"2016","unstructured":"Sanmamed MF, Chester C, Melero I, Kohrt H. Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(7):1190\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw041.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"24","key":"3038_CR50","doi-asserted-by":"publisher","first-page":"39021","DOI":"10.18632\/oncotarget.16547","volume":"8","author":"R Liu","year":"2017","unstructured":"Liu R, Wei H, Gao P, Yu H, Wang K, Fu Z, et al. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis. Oncotarget. 2017;8(24):39021\u201332. https:\/\/doi.org\/10.18632\/oncotarget.16547.","journal-title":"Oncotarget"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03038-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03038-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03038-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:24:15Z","timestamp":1762424655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03038-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["3038"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03038-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6954396\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"476"}}